Skip to main content

Correction: Inhibition of platelet activation suppresses reactive enteric glia and mitigates intestinal barrier dysfunction during sepsis

The Original Article was published on 27 October 2022

Correction : Molecular Medicine (2022) 28:127 https://doi.org/10.1186/s10020-022-00556-8

Following publication of the original article (Cheng et al. 2022), the authors informed us that in Figs. 1g and 5g, they mistakenly used the HE image of sham + Cliostazol group and the HE image of sham + 6877002 group. This correction does not affect the results and the conclusions of the study. The correct Figs. 1 and 5 are given in this correction.

Fig. 1
figure 1

Effect of inhibiting platelet activation on intestinal barrier function in septic mice. Cilostazol (10 mg/kg) was administrated orally 2 h prior to and at 12 h after CLP to inhibit platelet activation. 24 h after CLP, mice were sacrificed, and tissue samples were collected. a The survival rate of the mice within 7 days after CLP was observed by survival curves (n = 10). bf Intestinal barrier permeability was indicated by serum FITC-Dextran levels (b) (n = 6), water content (c) of gut (n = 6), and colony-forming units (CFUs) (df) from mesenteric lymph node (MLN), liver and lung (n = 6). g, h Haematoxylin and eosin (H&E) staining and pathological score, Scale bar = 100 μm (n = 6). i, j Western blot analysis of ZO-1 and occludin expression (n = 6). k, l TNF-α and IL-1β levels in intestinal tissues (n = 6). m, n Immunofluorescence staining analysis of ZO-1 (red), Scale bar = 50 μm (n = 6). The data are presented as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Fig. 5
figure 5

Blocking CD40L–CD40–TRAF6 signaling pathway improved intestinal barrier function in septic mice. Compound 6877002 (10 μmol/kg) was injected intraperitoneally 2 h prior to and at 12 h after CLP to block the CD40–TRAF6 signaling pathway. 24 h after CLP, mice were sacrificed, and tissue samples were collected. a The survival percentage of the mice was investigated within 7 days after CLP by survival curves (n = 10). Intestinal barrier permeability was indicated by serum FITC-Dextran levels b (n = 6), water content (c) of gut (n = 6), and colony-forming units (CFUs) df from mesenteric lymph node (MLN), liver and lung (n = 6). g, h Haematoxylin and eosin (H&E) staining and pathological score, Scale bar = 100 μm (n = 6). i, j Western blot analysis of ZO-1 and occludin expression (n = 6). k, l TNF-α and IL-1β levels in intestinal tissues (n = 6). m, n Immunofluorescence staining analysis of ZO-1 (red), Scale bar = 50 μm (n = 6). The data are presented as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Also, an error was identified in the Results section. The updated section is given below:

Results

Blocking CD40L–CD40–TRAF6 signaling pathway improved intestinal barrier function in septic mice

These results suggested that blocking CD40L–CD40–TRAF6 signaling pathway may be involved in the efficacy of cilostazol in ameliorating intestinal barrier dysfunction.

The original article (Cheng et al. 2022) has been corrected.

Reference

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yansong Li.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cheng, B., Du, M., He, S. et al. Correction: Inhibition of platelet activation suppresses reactive enteric glia and mitigates intestinal barrier dysfunction during sepsis. Mol Med 28, 149 (2022). https://doi.org/10.1186/s10020-022-00587-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s10020-022-00587-1